Anitha A, Banerjee Moinak
Rajiv Gandhi Center for Biotechnology, Poojappura, Trivandrum 695 014, India.
Int J Mol Med. 2003 Jan;11(1):125-31.
The human N-acetylation polymorphism is a genetic trait phenotypically reflected by differences in N-acetyltransferase (NAT) activity with therapeutic agents (rapid and slow acetylation). Acetylation polymorphism arises from the allelic variations in human arylamine N-acetyltransferase 2 gene (NAT2), which results in the production of NAT2 proteins with variable enzyme activity or stability. Certain NAT2 traits may contribute to the occurrence of adverse drug effects and act as susceptibility factors for certain malignancies such as bladder or lung cancer. We report the results of NAT2 genotyping of ethnic communities in South India. One hundred and sixty-six unrelated individuals belonging to eight Dravidian ethnic communities of South India, with typical Dravidian features, were genotyped for their acetylation status. Slow acetylators were found to be predominant in these populations, with a frequency of 74%. The allele 6A was found in the highest frequency, while 5B/6A was the most frequent genotype. A novel deletion at 859 site was observed in one of these communities; this heterozygous deletion was linked to a homozygous mutation at 481 site. The predominance of slow acetylator genotypes in our study populations conforms to the results in most other Asian populations, where approximately 60% of the individuals have been genotyped as slow acetylators. Sex specificity for acetylator status in our study varied from population to population.
人类的N - 乙酰化多态性是一种遗传特征,在表型上表现为使用治疗药物时N - 乙酰转移酶(NAT)活性的差异(快速和缓慢乙酰化)。乙酰化多态性源于人类芳胺N - 乙酰转移酶2基因(NAT2)的等位基因变异,这导致产生具有可变酶活性或稳定性的NAT2蛋白。某些NAT2特征可能导致药物不良反应的发生,并作为某些恶性肿瘤(如膀胱癌或肺癌)的易感因素。我们报告了印度南部不同种族群体的NAT2基因分型结果。对166名来自印度南部八个达罗毗荼种族群体、具有典型达罗毗荼特征的无关个体进行了乙酰化状态的基因分型。发现这些人群中慢乙酰化者占主导,频率为74%。等位基因6A的频率最高,而5B/6A是最常见的基因型。在其中一个群体中观察到859位点的一个新缺失;这种杂合缺失与481位点的纯合突变相关。我们研究人群中慢乙酰化者基因型的优势与大多数其他亚洲人群的结果一致,在其他亚洲人群中,约60%的个体被基因分型为慢乙酰化者。我们研究中乙酰化状态的性别特异性因群体而异。